| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 31 | 29.2x | 17.8x | Bottom tier | |
Growth | 91 | 17.3% | 7.1% | Top tier | |
Quality | 78 | 7.7% | 4.5% | Top tier | |
Safety | 96 | — | 2.6x | Top tier | |
Capital Return | 73 | — | 2.12% | Top tier | |
Momentum | 60 | 54.5% | 2.9% | Around median | |
Sentiment | 42 | 7 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Veracyte is a molecular oncology diagnostics company that generates most of its revenue from tests that help physicians classify cancer risk and choose the appropriate treatment or monitoring. Testing revenue reached $135.1 million of total revenue of $139.1 million in Q1 fiscal 2026, or approximately 97% of revenue, driven primarily by Decipher for prostate cancer and Afirma for thyroid nodules. The company is expanding its platform through Prosigna LDT for breast cancer and TrueMRD for detecting minimal residual disease, leveraging its existing commercial channels and clinical databases.
In Q2 fiscal 2026, revenue reached $150.3 million, up 15% year over year and approximately 8% compared with Q1 revenue of $139.1 million. Gross profit was $108.5 million, representing a calculated gross margin of approximately 72.2%, while net income reached $25.5 million and earnings per share were $0.31. Adjusted earnings before interest, taxes, depreciation, and amortization margin was also 29.2%, with those earnings growing 23% year over year.
For the twelve months ended in fiscal 2026, Veracyte recorded revenue of $561.9 million, gross profit of $403.0 million, net income of $114.5 million, and earnings per share of approximately $1.40. This represents a calculated gross margin of approximately 71.7% and a net income margin of approximately 20.4%, compared with revenue of $517.1 million and net income of $66.4 million in fiscal 2025.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $55.57, within a wide range of $44 to $69, with a consensus Buy rating. The average target is approximately 8.8% below the 52-week range high of $60.91, while the highest target exceeds that high; the wide range of targets reflects differing estimates regarding the sustainability of Decipher and Afirma growth and the success of Prosigna LDT and TrueMRD, and the data do not include a published earnings multiple that can be relied upon.
Figures in the text are as of 2026-08-31; the live price is shown at the top of the page.
Decipher and Afirma are driving most of the growth, as testing revenue rose to $135.1 million in Q1 fiscal 2026, up 26% year over year. Decipher volume grew 24% to approximately 28 thousand tests, while Afirma volume grew 12% to approximately 17,200 tests. In Q2 fiscal 2026, total revenue reached $150.3 million, representing 15% annual growth.
Decipher delivered 24% volume growth in Q1 fiscal 2026, while high-risk prostate cancer categories recorded growth of approximately 30%. The company says that only one in three men with prostate cancer in the United States currently benefits from the test, leaving room for expansion. The evidence base also includes four phase 3 trials that have completed enrollment, including GUIDANCE, which includes more than 2,000 patients.
Veracyte completed the full transition to the second-generation genomic analysis workflow in Q4 fiscal 2025. In Q1 fiscal 2026, a roughly 400-basis-point reduction in the no-result sample rate contributed to Afirma volume growth. The company expects an annual contribution of between two and three percentage points and raised its Afirma revenue growth outlook to a range extending from the high single digits to the low double digits.
Prosigna LDT targets a U.S. market that the company estimates at approximately 225 thousand patients annually with early-stage, hormone receptor-positive breast cancer. The test's opportunity is based on the randomized phase 3 OPTIMA trial, which included approximately 4,500 patients, but management tied the strength of the launch to meeting the primary endpoint and demonstrating non-inferiority. TrueMRD initially targets muscle-invasive bladder cancer and is supported by more than 10 studies in testing or analysis, 12 studies in contracting, and 29 studies in active planning.
The company recorded net income of $28.7 million in Q1 fiscal 2026 and $25.5 million in Q2 fiscal 2026. Net income for the twelve months ended in fiscal 2026 was approximately $114.5 million, with earnings per share of approximately $1.40. It also generated $35.2 million in operating cash flow in Q1 and ended the period with cash and short-term investments of $439.1 million.
Veracyte depends heavily on its testing business, which represented approximately 97% of Q1 fiscal 2026 revenue, and on continued momentum in Decipher and Afirma. Decipher also faces competition from digital pathology solutions and AI-assisted analysis, while TrueMRD requires market education and reimbursement coverage. In addition, revenue growth slowed from 21% in Q1 to 15% in Q2 fiscal 2026, and the adjusted earnings before interest, taxes, depreciation, and amortization margin declined from 30.8% to 29.2%.
